Back to Search
Start Over
The future of immune checkpoint therapy.
- Source :
-
Science (New York, N.Y.) [Science] 2015 Apr 03; Vol. 348 (6230), pp. 56-61. - Publication Year :
- 2015
-
Abstract
- Immune checkpoint therapy, which targets regulatory pathways in T cells to enhance antitumor immune responses, has led to important clinical advances and provided a new weapon against cancer. This therapy has elicited durable clinical responses and, in a fraction of patients, long-term remissions where patients exhibit no clinical signs of cancer for many years. The way forward for this class of novel agents lies in our ability to understand human immune responses in the tumor microenvironment. This will provide valuable information regarding the dynamic nature of the immune response and regulation of additional pathways that will need to be targeted through combination therapies to provide survival benefit for greater numbers of patients.<br /> (Copyright © 2015, American Association for the Advancement of Science.)
- Subjects :
- Antibodies, Monoclonal therapeutic use
Antibodies, Monoclonal, Humanized therapeutic use
Antineoplastic Agents pharmacokinetics
Biomarkers, Pharmacological
CTLA-4 Antigen antagonists & inhibitors
CTLA-4 Antigen immunology
Combined Modality Therapy
Humans
Inducible T-Cell Co-Stimulator Protein immunology
Ipilimumab
Lymphocyte Activation
Neoplasms pathology
Nivolumab
Signal Transduction immunology
T-Lymphocytes immunology
Tumor Microenvironment drug effects
Tumor Microenvironment immunology
Antineoplastic Agents therapeutic use
Immunotherapy methods
Immunotherapy trends
Neoplasms drug therapy
Signal Transduction drug effects
T-Lymphocytes drug effects
Subjects
Details
- Language :
- English
- ISSN :
- 1095-9203
- Volume :
- 348
- Issue :
- 6230
- Database :
- MEDLINE
- Journal :
- Science (New York, N.Y.)
- Publication Type :
- Academic Journal
- Accession number :
- 25838373
- Full Text :
- https://doi.org/10.1126/science.aaa8172